IBSA
17.3.2022 15:42:11 CET | Business Wire | Press release
Challenge, resilience, courage, nature, innovation. These are the keywords that characterise Sailing into the Future. Together , the new international project that sees IBSA (Institut Biochimique SA) the protagonist of a new three-year enterprise, which starts in 2022, albeit with a long-term vision.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220316005863/en/
“The project we are launching today is a real sporting endeavour, which sees us compete in some of the world’s most prestigious and challenging regattas”, stated Arturo Licenziati, President, CEO and Founder of IBSA . “This new project, however, is not only an ocean crossing, but also an opportunity to tell the values of IBSA, increasing its visibility around the world. In fact, IBSA is today an international company that maintains a vision that is always aimed at the future and ready to face challenges that go well beyond the therapeutic and personal care areas ”.
Founded in 1945 and headquartered in Lugano (Switzerland), IBSA is a leading scientific, economic and industrial reality in the pharmaceutical sector, thanks to the design outlined by Arturo Licenziati. A multinational company employing 2,000 people – including headquarters, subsidiaries and production sites – IBSA is present with its products in over 90 countries on 5 continents, with 16 subsidiaries located in Europe, China and the United States and with a turnover of over CHF 700 million.
“Innovating by keeping people at the core of our ecosystem, without ever setting limits: those are the horizons of the IBSA Group, which has always been inspired by the desire to go further ”, explained Licenziati . “ Sailing into the future. Together is a metaphor for our corporate history, but also a wish to grow and change, to find new means to offer health, well-being and new perspectives for the communities within which we operate, through social and environmental sustainability ”.
The project Sailing into the Future. Together engaged a team of great experience and sporting talent, involved right from the design and building phase of an innovative Class40 boat that will be led by Alberto Bona , the skipper who has been entrusted with the task of transforming this undertaking into a success.
“The Route du Rhum is the first stage of a three-year project: it’s one of the most challenging solo regattas in the world, as well as one of the most popular events in international ocean sailing. The project relies on a competent and greatly experienced team, while the conceptual design of the boat and its construction are entrusted to a successful duo: thus, we have all the credentials to put a winning boat in the water. The further challenge will be to make the most of the time available after the July launch, and carry out the in-water test part to make it reliable and performing ”, commented Alberto Bona . “Naturally, I thank our sponsor IBSA, with which I share the taste for the challenge, for continuous improvement, and the desire to break through new horizons. IBSA has chosen sailing to represent strength, determination, innovation, but also to raise awareness about a greater respect for nature, with a view to sustainability ”.
Beyond sport, and in a broader perspective, sailing is part of a path that brings the Company ever closer to the topic of sustainability , promoting respect for nature and the environment, but also to a new sensitivity and awareness about issues of collective responsibility , with activities in favour of people in difficulty or with disabilities.
“As part of this project, we decided to be a partner of some nautical clubs, in order to support inclusive sailing initiatives. We started a collaboration with the Yacht Club of Punta Ala (GR), to which we donated two boats for disabled children, to involve them in experiences in close contact with the sea, enabling them to navigate with accessible boats and compete in integrated races ”, explained Giorgio Pisani, Vice President Southern Europe and Project Leader . “The goal is to create an actual inclusion of the disabled on the competition field, promoting social integration as well as opportunities for dialogue, interaction and mutual understanding, thus helping break down barriers and differences ”.
The Company will also receive a prize during the award ceremony of the first edition (2022) of the Sport for Nature Awards – to be held today, March 17, 2022 – an event that aims to celebrate the “sport with a green soul”.
The award Azienda per il sociale: IBSA per la vela inclusiva (“Company for social initiatives: IBSA for inclusive sailing”) will be assigned precisely for raising awareness in favour of social and environmental sustainability through the values of sport, and in particular of sailing, as a means for social inclusion.
To narrate all the phases of the project Sailing into the Future. Together and accompany its development, the new website www.ibsasailing.com was created, also available in Italian and French . From here, it will be possible to follow the journey of skipper Alberto Bona, find out more about the Route du Rhum , the team and the new Class40 boat, that will set sail on November 6 from Saint-Malo, headed towards the island of Guadeloupe. In addition, the site will host photo and video content and news relating to IBSA’s social responsibility initiatives.
IBSA
IBSA (Institut Biochimique SA) is a multinational pharmaceutical Swiss Company, founded in 1945 in Lugano. Today, its products are present in over 90 Countries on 5 continents, through the Company’s 16 subsidiaries located in Europe, China and the United States. The company has a consolidated turnover of over 700 million Swiss francs, and employs 2,000 people between headquarters, subsidiaries and production sites. IBSA holds 90 families of approved patents and others in development, as well as a vast portfolio of products, covering 10 therapeutic areas: reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynaecology, cardio-metabolic, respiratory, consumer health. It is also one of the four largest operators worldwide in the area of Reproductive Medicine, and one of the world’s leaders in hyaluronic acid-based products. IBSA has based its philosophy on 4 pillars: Person, Innovation, Quality and Responsibility.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316005863/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stitch Raises $25M Series A Led by Andreessen Horowitz14.5.2026 09:00:00 CEST | Press release
In a16z’s first investment in the GCC, the Riyadh-based fintech positions itself as the unified infrastructure layer for financial institutions worldwide Stitch, the operating system built for modern financial institutions, today announced it has raised $25 million in Series A funding led by Andreessen Horowitz (a16z). The investment marks a16z’s first in the GCC and brings Stitch’s total funding to $35 million. In addition to a16z, existing investors Arbor Ventures, COTU Ventures, Raed Ventures, and SVC also participated in the round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514070694/en/ Mohamed Oueida - Founder & CEO, Stitch (Photo: AETOSWire) Despite spending over $1 trillion on digital transformation in the last three years, most financial institutions are still running on the same fragmented, legacy infrastructure that has defined the sector for decades. Globally, banks spend $700 billion a year on technology
Corona Global Named Most Valuable Beer Brand in Kantar BrandZ Rankings for Third Consecutive Year14.5.2026 06:01:00 CEST | Press release
AB InBev Holds 8 of the Top 10 Most Valuable Beer Brands Globally Corona global has been recognized as the most valuable beer brand in the world for the third consecutive year in Kantar's BrandZ 2026 Most Valuable Global Brands report, released today. Eight out of the top ten most valuable global beer brands belong to AB InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD), according to the report ranking the best brands in the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513211378/en/ In 2025, Corona led AB InBev’s performance, increasing revenue by 8.3% outside of its home market with double-digit volume growth in 30 markets, while Corona Cero delivered strong double-digit volume growth. As the brand celebrated its 100th anniversary, Corona launched its global “Corona 100” platform, including a multi-year sponsorship of a renowned concert at Copacabana Beach in Rio de Janeiro. Strong momentum continued in Q1 2026
The Bolivarian Republic of Venezuela Announces the Initiation of a Comprehensive Public Debt Restructuring Process13.5.2026 22:08:00 CEST | Press release
The Bolivarian Republic of Venezuela announces today its decision to initiate a comprehensive restructuring of its external public debt obligations. CONTEXT & RATIONALE Over the past decade, Venezuela's economy has been severely impacted by external shocks – from the end of the commodity super-cycle to foreign sanctions and COVID-19 – resulting in a sharp economic contraction, a protracted default since 2017, and a ballooning of public sector liabilities. The country nonetheless possesses a strong economic potential, including unique hydrocarbon and mineral endowments. A recovery is underway, and Venezuela is committed to accelerating it through a comprehensive reform agenda in support of growth, fiscal sustainability, monetary stabilization, and enhanced governance. Restoring public debt sustainability is central to this agenda: the current debt overhang constrains external financing, limits public investment capacity, and prevents full re-engagement with the international financial s
Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise13.5.2026 21:00:00 CEST | Press release
Proposed acquisition extends Boomi’s AI gateway capabilities, enabling enterprises to govern massive volumes of traffic for production-ready AI Boomi, the data activation company for AI, today announced it has signed a letter of intent to acquire Lunar.dev, an innovator in AI and MCP gateway. The proposed acquisition is expected to enrich the Boomi Enterprise Platform and Boomi Connect with advanced capabilities to govern and scale AI usage across enterprise systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513850557/en/ Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise As organizations move from AI experimentation to production, controlling how agents and AI applications interact with LLMs at scale has become critical. Lunar.dev addresses this need with an AI gateway that delivers granular, policy-driven control over AI interactions, with the visibility, securi
BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma13.5.2026 19:27:00 CEST | Press release
BEQALZI is a foundational BCL2 inhibitor designed for greater potency and selectivity, with potential to improve efficacy, tolerability, and convenience versus others in the classApproval of BEQALZI marks the first new BCL2 inhibitor approved in a decade in the U.S. and the only BCL2 inhibitor approved in MCL, aiming to set a new standard of innovation BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI™(bee-KAHL-zee; sonrotoclax), a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. BEQALZI was designed to enhance BCL2 inhibition—with greater potency, selectivity, and a pharmacologic profile with potential to improve efficacy, tolerability, a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
